Yvonne Jeng ’16 pitched Alexion Pharmaceuticals (ALXN) to the Student Managed Investment Fund (SMIF) on January 27, 2016. Alexion is a biotechnology company that is focused on the research, development, and commercialization of antibody therapeutics for life-threatening, ultra-rare diseases. The company’s mission is to develop life-transforming therapies for patients with rare diseases and deliver medical breakthroughs where none currently exist. Three drugs lead Alexion’s rare disease-focused pipeline: Soliris, Strensiq, and Kanuma. Most notable is Soliris, the company’s billion-dollar blockbuster. Alexion has over 20 drug candidates in its pipeline, which spans several therapeutic areas. Many of them have the potential to become first-in-class therapies for patients with severe and life-threatening disorders. Alexion has experienced exceptional revenue growth throughout the past few years. The company’s future will reside in the orphan drug market, a rapidly growing but incredibly risky market.